CANbridge Pharmaceuticals CAN108 new drug application for Alagille syndrome accepted by China’s National Medical Products Administration

17 January 2022 - Priority review expected to be granted. ...

Read more →

Basilea announces approval of antifungal Cresemba (isavuconazole) for invasive aspergillosis in China

13 January 2022 - Second approved indication after invasive mucormycosis in December 2021. ...

Read more →

Ligand’s Partner CStone Pharmaceuticals receives approval in China for sugemalimab (Cejemly) for the first-line treatment of advanced non-small-cell lung cancer in combination with chemotherapy

22 December 2021 - Sugemalimab was discovered using the OmniAb platform. ...

Read more →

Chinese official a ‘hero’ after forcing US drug maker Biogen to cut cost of treatment for spinal disease with ‘gentle but firm’ approach

6 December 2021 - US pharmaceutical company reduces the price of a drug for a rare spinal disease after seven rounds ...

Read more →

New hope offered to rare disease patients

14 December 2021 - Early this month, the world's first therapy to treat spinal muscular atrophy, a rare genetic disorder ...

Read more →

Junshi Biosciences announces NMPA accepted supplemental new drug application for toripalimab in combination with chemotherapy as first-line treatment of advanced NSCLC

10 December 2021 - Sixth indication for toripalimab submitted in China. ...

Read more →

Henlius' fourth biologic bevacizumab biosimilar approved by National Medical Products Administration

3 December 2021 - Shanghai Henlius Biotech announced that bevacizumab biosimilar, developed and manufactured by Henlius independently, has been approved by ...

Read more →

InnoCare announces inclusion of orelabrutinib in China National Reimbursement Drug List

2 December 2021 - InnoCare Pharma announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement ...

Read more →

Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA as first COVID-19 neutralising antibody combination therapy in China

8 December 2021 - The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, through a randomised, double-blind ...

Read more →

Zai Lab announces inclusion of Zejula (niraparib) in China’s National Reimbursement Drug List for first-line ovarian cancer

3 December 2021 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration ...

Read more →

China clears insurance coverage for Kainos Medicine’s HIV drug

6 December 2021 - A home-grown HIV treatment developed by Kainos Medicine and out-licensed to China’s Jiangsu Aidea Pharmaceuticals has ...

Read more →

Ascletis announces inclusion in new catalogue of China National Reimbursement Drug List of Asclevir/Ganovo regimen, an all oral direct anti-HCV therapy

2 December 2021 - Ascletis Pharma today announces that its all-oral direct anti-hepatitis C virus Asclevir (ravidasvir)/Ganovo (danoprevir) regimen has been ...

Read more →

BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of tislelizumab in three new indications, Brukinsa (zanubrutinib) in one new indication, and the first listing for pamiparib

2 December 2021 - BeiGene today announced that three of its medicines have been added to the most recent National Reimbursement ...

Read more →

Junshi Biosciences announces two additional indications for toripalimab included in China’s National Reimbursement Drug List

3 December 2021 - The only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinoma. ...

Read more →

Drug makers cut prices by 62% on average to get China state insurance listing

4 December 2021 - Pharmaceutical firms have agreed to cut prices by 61.7% on average for 67 medicines to be ...

Read more →